4CPS-122 Efficacy of different chemotherapy regimens associated with trastuzumab in her2-positive advanced gastric cancer: data from the national register agamenon

BACKGROUND: The Phase III TOGA study confirmed an increased survival for patients with HER2-positive advanced gastric cancer (AGC) treated with trastuzumab in combination with cisplatin and fluoropyrimidine (CF). However, there is little information on trastuzumab activity in combination with other...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Eur J Hosp Pharm
Autori principali: Torròn, A Martinez, Alvarez-Manceñido, F, Garcia, I Zapico, Palomo, A Rodriguez, Calero, M Alaguero, Carmona-Bayonas, A, Reguera, P, Aguado, G, Sánchez, A, Lozano-Blázquez, A
Natura: Artigo
Lingua:Inglês
Pubblicazione: BMJ Group 2018
Soggetti:
Section 4: Clinical pharmacy services
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7535424/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.213
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi